Keay Nakae
Stock Analyst at Chardan Capital
(3.95)
# 753
Out of 4,479 analysts
168
Total ratings
30.66%
Success rate
17.92%
Average return
Main Sectors:
29 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLN Silence Therapeutics | Maintains: Buy | $42 → $55 | $18.06 | +204.54% | 7 | Jun 28, 2024 | |
| RNA Avidity Biosciences | Maintains: Buy | $33 → $45 | $38.80 | +15.98% | 9 | Jun 12, 2024 | |
| OBIO Orchestra BioMed Holdings | Reiterates: Buy | $20 | $7.44 | +168.82% | 6 | Jun 12, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $4 | $3.13 | +27.80% | 8 | Jun 5, 2024 | |
| COYA Coya Therapeutics | Maintains: Buy | $14 | $6.05 | +131.40% | 12 | Jun 5, 2024 | |
| IBIO iBio, Inc. | Maintains: Buy | $5 | $1.95 | +156.41% | 2 | Jun 3, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $60 | $25.22 | +137.91% | 10 | Jun 3, 2024 | |
| SONN Sonnet BioTherapeutics Holdings | Maintains: Buy | $30 | $0.88 | +3,309.09% | 10 | May 28, 2024 | |
| SABS SAB Biotherapeutics | Maintains: Buy | $25 | $2.86 | +774.13% | 9 | May 21, 2024 | |
| DYN Dyne Therapeutics | Maintains: Buy | $31 → $42 | $34.65 | +21.21% | 6 | May 21, 2024 | |
| NTBL Notable Labs | Maintains: Buy | $7 → $5 | $0.58 | +759.99% | 2 | May 16, 2024 | |
| ALUR Allurion Technologies | Maintains: Buy | $5 | $1.26 | +296.83% | 2 | May 15, 2024 | |
| PRQR ProQR Therapeutics | Maintains: Buy | $2.5 | $1.65 | +51.98% | 9 | May 10, 2024 | |
| MCRB Seres Therapeutics | Maintains: Buy | $8 → $6 | $0.70 | +755.92% | 5 | May 8, 2024 | |
| OMGA Omega Therapeutics | Maintains: Buy | $7 | $2.07 | +238.16% | 5 | May 7, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $225 | $247.61 | -9.13% | 6 | May 3, 2024 | |
| FEMY Femasys | Maintains: Buy | $12 | $1.11 | +981.08% | 8 | Apr 1, 2024 | |
| GANX Gain Therapeutics | Reiterates: Buy | $6 | $1.20 | +402.09% | 5 | Mar 27, 2024 | |
| SYBX Synlogic | Downgrades: Neutral | n/a | $1.43 | - | 5 | Feb 9, 2024 | |
| BTTX Better Therapeutics | Reiterates: Buy | $9 | $0.01 | +69,130.77% | 6 | Aug 10, 2023 | |
| MESO Mesoblast | Maintains: Sell | $8 → $6 | $6.45 | -6.98% | 7 | Aug 4, 2023 | |
| EVLO Evelo Biosciences | Downgrades: Neutral | $50 | $0.04 | +124,900.00% | 3 | Nov 16, 2022 | |
| PHGE BiomX | Maintains: Buy | $6 → $2 | $0.35 | +468.83% | 4 | Nov 10, 2022 | |
| EBS Emergent BioSolutions | Maintains: Buy | $65 → $55 | $7.49 | +634.31% | 8 | Nov 9, 2022 | |
| NBSE NeuBase Therapeutics | Downgrades: Neutral | n/a | $0.38 | - | 5 | Oct 17, 2022 | |
| XCUR Exicure | Maintains: Neutral | $0.25 → $2 | $0.31 | +544.75% | 3 | Aug 16, 2022 | |
| FBRX Forte Biosciences | Upgrades: Neutral | n/a | $0.52 | - | 2 | Sep 20, 2021 | |
| OCGN Ocugen | Downgrades: Neutral | n/a | $1.61 | - | 2 | Feb 9, 2021 | |
| OCX OncoCyte | Downgrades: Neutral | n/a | $2.96 | - | 2 | Jun 30, 2020 |
Silence Therapeutics
Jun 28, 2024
Maintains: Buy
Price Target: $42 → $55
Current: $18.06
Upside: +204.54%
Avidity Biosciences
Jun 12, 2024
Maintains: Buy
Price Target: $33 → $45
Current: $38.80
Upside: +15.98%
Orchestra BioMed Holdings
Jun 12, 2024
Reiterates: Buy
Price Target: $20
Current: $7.44
Upside: +168.82%
Arbutus Biopharma
Jun 5, 2024
Maintains: Buy
Price Target: $4
Current: $3.13
Upside: +27.80%
Coya Therapeutics
Jun 5, 2024
Maintains: Buy
Price Target: $14
Current: $6.05
Upside: +131.40%
iBio, Inc.
Jun 3, 2024
Maintains: Buy
Price Target: $5
Current: $1.95
Upside: +156.41%
Arrowhead Pharmaceuticals
Jun 3, 2024
Maintains: Buy
Price Target: $60
Current: $25.22
Upside: +137.91%
Sonnet BioTherapeutics Holdings
May 28, 2024
Maintains: Buy
Price Target: $30
Current: $0.88
Upside: +3,309.09%
SAB Biotherapeutics
May 21, 2024
Maintains: Buy
Price Target: $25
Current: $2.86
Upside: +774.13%
Dyne Therapeutics
May 21, 2024
Maintains: Buy
Price Target: $31 → $42
Current: $34.65
Upside: +21.21%
Notable Labs
May 16, 2024
Maintains: Buy
Price Target: $7 → $5
Current: $0.58
Upside: +759.99%
Allurion Technologies
May 15, 2024
Maintains: Buy
Price Target: $5
Current: $1.26
Upside: +296.83%
ProQR Therapeutics
May 10, 2024
Maintains: Buy
Price Target: $2.5
Current: $1.65
Upside: +51.98%
Seres Therapeutics
May 8, 2024
Maintains: Buy
Price Target: $8 → $6
Current: $0.70
Upside: +755.92%
Omega Therapeutics
May 7, 2024
Maintains: Buy
Price Target: $7
Current: $2.07
Upside: +238.16%
Alnylam Pharmaceuticals
May 3, 2024
Maintains: Buy
Price Target: $225
Current: $247.61
Upside: -9.13%
Femasys
Apr 1, 2024
Maintains: Buy
Price Target: $12
Current: $1.11
Upside: +981.08%
Gain Therapeutics
Mar 27, 2024
Reiterates: Buy
Price Target: $6
Current: $1.20
Upside: +402.09%
Synlogic
Feb 9, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.43
Upside: -
Better Therapeutics
Aug 10, 2023
Reiterates: Buy
Price Target: $9
Current: $0.01
Upside: +69,130.77%
Mesoblast
Aug 4, 2023
Maintains: Sell
Price Target: $8 → $6
Current: $6.45
Upside: -6.98%
Evelo Biosciences
Nov 16, 2022
Downgrades: Neutral
Price Target: $50
Current: $0.04
Upside: +124,900.00%
BiomX
Nov 10, 2022
Maintains: Buy
Price Target: $6 → $2
Current: $0.35
Upside: +468.83%
Emergent BioSolutions
Nov 9, 2022
Maintains: Buy
Price Target: $65 → $55
Current: $7.49
Upside: +634.31%
NeuBase Therapeutics
Oct 17, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.38
Upside: -
Exicure
Aug 16, 2022
Maintains: Neutral
Price Target: $0.25 → $2
Current: $0.31
Upside: +544.75%
Forte Biosciences
Sep 20, 2021
Upgrades: Neutral
Price Target: n/a
Current: $0.52
Upside: -
Ocugen
Feb 9, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.61
Upside: -
OncoCyte
Jun 30, 2020
Downgrades: Neutral
Price Target: n/a
Current: $2.96
Upside: -